129.70
前日終値:
$130.71
開ける:
$130.62
24時間の取引高:
889.91K
Relative Volume:
0.80
時価総額:
$13.02B
収益:
$2.86B
当期純損益:
$478.60M
株価収益率:
27.79
EPS:
4.6676
ネットキャッシュフロー:
$748.70M
1週間 パフォーマンス:
+1.50%
1か月 パフォーマンス:
-0.31%
6か月 パフォーマンス:
-10.69%
1年 パフォーマンス:
+17.58%
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
名前
Neurocrine Biosciences Inc
セクター
電話
(858) 617-7600
住所
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Compare NBIX vs TAK, ZTS, HLN, TEVA, UTHR
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
NBIX
Neurocrine Biosciences Inc
|
129.70 | 13.02B | 2.86B | 478.60M | 748.70M | 4.6676 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.11 | 57.21B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.99 | 48.96B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.23 | 45.55B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.44 | 34.29B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
527.00 | 23.10B | 3.18B | 1.33B | 1.04B | 27.90 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-02-24 | 開始されました | Wolfe Research | Outperform |
| 2026-01-08 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2025-10-21 | 開始されました | Citigroup | Buy |
| 2025-07-21 | 開始されました | Truist | Buy |
| 2025-07-10 | 開始されました | Goldman | Buy |
| 2025-04-15 | アップグレード | Needham | Hold → Buy |
| 2025-04-14 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-02-11 | 開始されました | Deutsche Bank | Hold |
| 2024-10-10 | 再開されました | Raymond James | Outperform |
| 2024-08-29 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | 再開されました | Citigroup | Neutral |
| 2023-12-12 | 開始されました | Deutsche Bank | Buy |
| 2023-10-24 | 再開されました | Cantor Fitzgerald | Overweight |
| 2023-08-21 | 繰り返されました | Mizuho | Neutral |
| 2023-07-24 | アップグレード | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | アップグレード | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-03-30 | アップグレード | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | アップグレード | Evercore ISI | In-line → Outperform |
| 2023-02-03 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | ダウングレード | Evercore ISI | Outperform → In-line |
| 2022-10-11 | 開始されました | UBS | Buy |
| 2022-09-26 | 開始されました | Wells Fargo | Equal Weight |
| 2022-06-06 | 再開されました | Jefferies | Buy |
| 2022-03-03 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | アップグレード | Goldman | Neutral → Buy |
| 2022-01-18 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | 開始されました | BMO Capital Markets | Underperform |
| 2021-11-17 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-10-14 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | 再開されました | Needham | Hold |
| 2021-08-06 | ダウングレード | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | 再開されました | Goldman | Neutral |
| 2021-05-06 | アップグレード | Barclays | Equal Weight → Overweight |
| 2021-02-02 | 開始されました | Raymond James | Outperform |
| 2020-09-30 | 開始されました | The Benchmark Company | Hold |
| 2020-08-04 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-06-29 | ダウングレード | Goldman | Buy → Neutral |
| 2020-06-09 | 開始されました | Wedbush | Outperform |
| 2020-03-06 | 開始されました | Citigroup | Buy |
| 2020-02-27 | 開始されました | Barclays | Equal Weight |
| 2020-02-24 | 開始されました | William Blair | Outperform |
| 2020-02-06 | 開始されました | Mizuho | Neutral |
| 2020-02-05 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-12-13 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | 開始されました | RBC Capital Mkts | Outperform |
| 2019-07-16 | 開始されました | Oppenheimer | Outperform |
| 2019-06-05 | 開始されました | Guggenheim | Neutral |
| 2019-05-21 | 開始されました | Credit Suisse | Outperform |
| 2019-04-22 | アップグレード | JP Morgan | Neutral → Overweight |
| 2019-04-12 | 開始されました | Evercore ISI | Outperform |
| 2019-02-06 | 繰り返されました | BofA/Merrill | Buy |
| 2019-01-23 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2018-12-13 | 開始されました | Goldman | Buy |
| 2018-11-21 | 開始されました | Canaccord Genuity | Buy |
すべてを表示
Neurocrine Biosciences Inc (NBIX) 最新ニュース
Wolfe Research initiates coverage of Neurocrine Biosciences (NBIX) with outperform recommendation - MSN
Neurocrine expects INGREZZA sales to reach up to $2.8B in 2026 amid CRENESSITY launch momentum - MSN
Truist lowers Neurocrine Biosciences, Inc.’s (NBIX) PT following 2026 outlook update - MSN
Neurocrine Biosciences promotes Andrew Ratz to operations chief By Investing.com - Investing.com South Africa
Neurocrine at Stifel CNS Forum: Growth and Strategic Focus - Investing.com
Transcript : Neurocrine Biosciences, Inc. Presents at Stifel 2026 Virtual CNS Forum, Mar-17-2026 04 - marketscreener.com
Neurocrine Biosciences (NBIX) CTO Ratz reports initial stock and option grants - Stock Titan
Neurocrine Biosciences promotes Andrew Ratz to operations chief - Investing.com
Neurocrine Biosciences promotes Andrew Ratz to chief technical operations officer - StreetInsider
Neurocrine Biosciences Appoints Andrew Ratz, Ph.D., as Chief Technical Operations Officer - PR Newswire
Morgan Stanley Lifts PT on Neurocrine Biosciences (NBIX) to $150 From $148, Keeps Overweight Rating - MSN
Neurocrine Biosciences: The Song Remains The Same (NASDAQ:NBIX) - Seeking Alpha
Iron Triangle Partners LP Acquires New Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Distillate Capital Partners LLC Trims Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Boone Capital Management Decreases Stake in Neurocrine Biosciences - National Today
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Braidwell LP - MarketBeat
Boone Capital Management LLC Has $23.36 Million Stake in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Assessing Neurocrine Biosciences (NBIX) Valuation After GARP Recognition And Reaffirmed Confidence In Ingrezza - simplywall.st
Dodge & Cox Decreases Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
2Xideas AG Trims Stock Position in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Swiss National Bank Sells 14,100 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Top GARP Pick with Strong Growth and a Reasonable Price - ChartMill
Connor Clark & Lunn Investment Management Ltd. Acquires 32,480 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NASDAQ:NBIX) Given New $177.00 Price Target at JPMorgan Chase & Co. - MarketBeat
Neurology stocks rebound in 2025 after midyear slump - bioworld.com
Magnetar Financial LLC Acquires New Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Korea Investment CORP Has $10.06 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
First Trust Advisors LP Has $50.97 Million Stock Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Capital Fund Management S.A. Has $17.37 Million Holdings in Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Is It Time To Reassess Neurocrine Biosciences (NBIX) After The Recent Share Price Pullback - simplywall.st
A Look At Neurocrine Biosciences (NBIX) Valuation After Recent Share Price Pullback - Yahoo Finance
Victory Capital Management Inc. Buys 31,981 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Cantor Fitzgerald Keeps Overweight on NBIX Neurocrine Biosciences March 2026 - Meyka
Neurocrine Biosciences to Present at the Stifel 2026 Virtual CNS Forum - PR Newswire
Cantor Fitzgerald raises Neurocrine Bio price target on Ingrezza outlook By Investing.com - Investing.com Canada
Barclays Increases Stake in Neurocrine Biosciences - National Today
Neurocrine Biosciences, Inc. $NBIX Shares Bought by Barclays PLC - MarketBeat
American Century Companies Inc. Sells 52,349 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Transcript : Neurocrine Biosciences, Inc. Presents at Leerink Global Healthcare Conference 2026, Mar-09-2026 08 - marketscreener.com
The Technical Signals Behind (NBIX) That Institutions Follow - Stock Traders Daily
Rhenman & Partners Asset Management Trims Neurocrine Biosciences Stake - National Today
Rhenman & Partners Asset Management AB Sells 34,500 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
14,653 Shares in Neurocrine Biosciences, Inc. $NBIX Acquired by Munich Reinsurance Co Stock Corp in Munich - MarketBeat
What insider trading reveals about Neurocrine Biosciences Inc. stockM&A Rumor & Reliable Entry Point Alerts - Naître et grandir
Equifax Expands Data Solutions While Neurocrine Biosciences Advances Neurological Treatment Research - geneonline.com
Two stocks flagged for study: Equifax and Neurocrine Bio review - Stock Titan
Focus Partners Advisor Solutions LLC Buys 8,011 Shares of Neurocrine Biosciences, Inc. $NBIX - MarketBeat
Neurocrine Biosciences (NBIX) CFO discloses bona fide gift of shares - Stock Titan
Neurocrine Biosciences, Inc. $NBIX Shares Sold by Teachers Retirement System of The State of Kentucky - MarketBeat
GW&K Investment Management Trims Neurocrine Biosciences Stake - National Today
Neurocrine Biosciences Inc (NBIX) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):